Navigation Links
Angiotech Pharmaceuticals announces FDA approval of TAXUS(R) Liberte(R) Long Stent
Date:7/16/2009

the TAXUS Express Stent (3.5% vs. 9.4%, p=0.0426). The rate of stent thrombosis at two years was zero percent for the TAXUS Liberte Long Stent and 0.8 percent for the TAXUS Express Stent(2).

"Today's approval of the TAXUS Liberte Long Stent, along with the approval of the TAXUS Liberte Atom(TM) Stent in May, demonstrates the strength and breadth of the paclitaxel platform," said Dr. William Hunter, President and CEO of Angiotech. "We are pleased with the progress that Boston Scientific continues to make with TAXUS stents."

Boston Scientific has the industry's widest range of coronary stent sizes. The TAXUS Liberte Stent Series is now available in 92 sizes, ranging from 2.25 mm to 4.0 mm in diameter and from 8 mm to 38 mm in length.

TAXUS Stents have been evaluated by the industry's most extensive randomized, controlled clinical trial program, with follow-up to five years in some cases. These trial results have been supplemented by data on more than 35,000 patients enrolled in post-approval registries. To date, approximately 11 million Boston Scientific stents have been implanted globally, making them the world's most frequently used stents.

    -----------------------------
    (1) Percentage estimates from April 2009 Millennium Research Group report
        and ARRIVE 1 and 2 registries.

    (2) In the TAXUS ALTAS Long Lesion Trial, the TAXUS Liberte Long (38mm)
        Stent met its primary endpoint of non-inferiority to the TAXUS
        Express control Stent in nine-month percent diameter stenosis (31.7%
        vs. 32.6%, p=0.71) and reported a 36 percent reduction in
        MACE (9.4% vs. 14.8%, p=0.16).

    Forward Looking Statements
    --------------------------

Statements contained in this press release that are not based on historical fact, including without limitation statements containing the words "believes," "may," "plans," "will," "estimates," "continues," "anticipates," "intends
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Angiotech Pharmaceuticals, Inc. announces conference call and webcast
2. Angiotech Pharmaceuticals announces FDA 510(k) clearance of the Option(TM) Inferior Vena Cava Filter
3. Angiotech Enters License, Distribution and Supply Agreements for Fibrin and Thrombin Technologies with Haemacure Corporation
4. Angiotech Pharmaceuticals announces FDA approval of next-generation TAXUS(R) Liberte(R) Atom(TM) Stent system
5. Angiotechs corporate partner, Boston Scientific, announces launch of third-generation TAXUS(R) Element(TM) Stent
6. Angiotech launches e-commerce website that allows customers to order Quill(TM) SRS product line
7. Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009
8. Angiotech announces date of annual general meeting of shareholders
9. Angiotech Pharmaceuticals, Inc. Announces Conference Call And Webcast
10. Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc.
11. Angiotech announces positive results from Bio-Seal(TM) clinical study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... -- Pomerantz LLP is investigating claims on behalf of investors ... IPXL).  Such investors are advised to contact Robert ... ext. 237. The investigation concerns whether Impax ... Sections 10(b) and 20(a) of the Securities Exchange Act ... Impax Laboratories, Inc. (the "Company") issued a press release ...
(Date:7/29/2014)... , July 29, 2014 /PRNewswire-iReach/ -- Nanosyn, Inc. ... FORMA Therapeutics, Inc., to provide access to Nanosyn,s ... lead discovery platform for novel small molecule therapeutics. ... the opportunity to work with FORMA Therapeutics to ... and protein homeostasis. FORMA Therapeutics, decision to work ...
(Date:7/29/2014)... July 29, 2014 TransVac Solutions, the ... collection and transport solutions for hospitals, will be exhibiting ... Engineering (ASHE) Annual Conference & Technical Exhibition Aug. 3-6 ... its technology for making hospitals cleaner, reducing infection risk ... the hospital’s life cycle. Staff will be available ...
(Date:7/29/2014)...  Sigma-Aldrich Corporation (NASDAQ: SIAL ) dramatically ... investment in Green Chemistry and donated more than 8,000 ... the Company announced Monday in its new 2013 ... The report comes in a year ... responsible corporate citizen, including recognition for the second consecutive ...
Breaking Biology Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Impax Laboratories, Inc. - IPXL 2Nanosyn Announces Expanded Partnership With FORMA Therapeutics 2TransVac Presents Cost Saving Technology at ASHE Conference for Keeping Hospitals Cleaner 2Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 2Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 3
... Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced ... present during the 11th Annual BIO CEO & Investor,Conference ... The presentation,will be webcast from the Waldorf-Astoria Hotel ... To access the presentation via the Web, please go ...
... Feb. 3 Genomic Health,Inc. (Nasdaq: GHDX ) ... and year ended December 31, 2008. , ... to $31.2 million,compared with $19.3 million in the fourth quarter ... assay was $30.9 million in the fourth,quarter of 2008, an ...
... Feb. 3 /PRNewswire-FirstCall/ - Victhom Human Bionics Inc., ... has obtained CE Mark approval for its Neurostep(TM) ... system (CLS) used on peripheral nerves. CE Mark ... the Neurostep(TM) in any of the Member States ...
Cached Biology Technology:Alexza's Corporate Presentation to be Webcast at the 11th Annual BIO CEO & Investor Conference 2Alexza's Corporate Presentation to be Webcast at the 11th Annual BIO CEO & Investor Conference 3Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 2Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 3Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 4Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 5Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 6Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 7Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 8Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 9Victhom Human Bionics Receives CE Mark for the Neurostep(TM) System, the World's First Fully Implantable Closed-Loop Neuromodulation Therapy for Treatment of Foot Drop 2Victhom Human Bionics Receives CE Mark for the Neurostep(TM) System, the World's First Fully Implantable Closed-Loop Neuromodulation Therapy for Treatment of Foot Drop 3
(Date:7/29/2014)... an easier method to create DNAprotein conjugates. The ... diagnosing diseases. , DNA linked to proteins ... can be used in diagnostic techniques, nanotechnology and ... with DNA can be used for purposes ... biological material. The method also provides easier access ...
(Date:7/29/2014)... the University of Kent has shown for the first ... a breakthrough that could have a major impact on ... of Biosciences uncovered the mechanism whereby the physical properties ... actin filaments are ,fine-tuned, to undertake different functions. ... completely stable, providing a framework for the cell, others ...
(Date:7/29/2014)... to go and almost 2500 registered participants, the final ... The event, a joint venture between the Federation of ... for Biochemistry and Molecular Biology (SFBBM), will take place ... the Palais des Congrs in Paris, France. , The ... life sciences in Europe this year. It features more ...
Breaking Biology News(10 mins):New method provides researchers with efficient tool for tagging proteins 2Counting down to FEBS-EMBO 2014 in Paris, France 2
... fattening than others? What about the risks of bariatric ... (ASN) on December 5-7 for answers to these questions ... Nutrition Conference. The 3-day program delivers valuable ... satellite sessions, and networking opportunities. Credentialed media, science writers ...
...   The Bensalem Township Police Department , in conjunction with ... of DNA testing.  This pilot program known as " BodeHITS ... kind in the country for law enforcement. Bensalem ... with over 6,000 DNA profiles consisting of evidence and reference/individual ...
... , Nov. 19, 2013 Nelson Laboratories ( www.nelsonlabs.com ... (#321) during BIOMEDevice in San ... Thor Rollins, biocompatibility specialist. Those interested in a consultation ... http://photos.prnewswire.com/prnh/20120727/LA47745LOGO ) Rollins will also present, ...
Cached Biology News:Advances and Controversies in Clinical Nutrition: Diet, Technology and Practice 290 Minute DNA Results, A First Of Its Kind, Coming To Bensalem 2Nelson Laboratories to Offer Free Biocompatibility Consultations During BIOMEDevice San Jose 2
Mouse monoclonal [HL-37] to HLA DQ1 + HLA DQ3 ( Abpromise for all tested applications)....
SHEEP ANTI BOVINE BETA-LACTOGLOBULIN A...
... Convenient platform for tube handling and reagent dispensing ... tubes - 96 x 0.3ml U-bottom ... - Thermo-Fast® 96 Non-Skirted Plate - ... x 0.5ml Thermo-Tubes Multiple workstations can be securely stacked ...
6B9...
Biology Products: